Residual DNA testing market to be valued at $370m by 2030

India, China, Brazil, and Japan are rapidly scaling their biopharma capabilities.

The global residual DNA testing market is projected to reach $370m by 2030 at a compound annual growth rate of 6%, according to MarketsandMarkets.

Markets such as India, China, Brazil, and Japan are rapidly scaling their biopharma capabilities by investing in precision testing and validation tools.

“[This makes them] ripe for residual DNA tech adoption as they chase global compliance standards,” the report said.

However, standardisation remains a challenge, with varying protocols hindering market growth.

“Companies must invest in platform standardisation, cross-site validation, and training frameworks to ensure regulatory alignment and scalable operations,” it added.